• br DGAT proteins lipid droplets

  2019-11-29

  

  DGAT proteins, lipid droplets and cancer cells Conclusions and future directions Conflicts of interest Acknowledgements This work was supported by NIH grants GM062887, P01CA097132, and Veterans Affairs Merit Award to LMO. Introduction Bioethanol and biodiesel are regarded as the two

• Our recent discovery M P H R A S of

  2019-11-29

  

  Our recent discovery (M.P., H.R., A.S.) of a highly selective and in vivo active DDR1 small-molecule inhibitor provides evidence that DDR1 is a druggable pharmaceutical target, and some details of our efforts are provided below. To avoid the repurposing of known kinase inhibitor structural motifs, w

• The present study has shown that additional protein stabilit

  2019-11-29

  

  The present study has shown that additional protein stability can be achieved (Fig. 6). The 0.6 to 1.0 °C increases that were observed were not large compared, for example, to the ∼5 °C increase that has been reported using sequence modifications [22]. This may reflect that the Hyp enters both the X

• The crystal structure of full length CHK is still

  2019-11-29

  

  The crystal structure of full-length CHK is still unsolved. However, the close homology between CHK and Csk suggests that these kinases share a similar structure. Therefore, the engagement of the CHK SH2–kinase linker with the αC-helix could control the activity of the CHK kinase domain. Sequence al

• br Conclusion The past few years

  2019-11-29

  

  Conclusion The past few years have witnessed substantial progress in understanding the structural mechanisms of substrate recognition and the reactions catalyzed by the O-GlcNAc-cycling enzymes, but more work remains. In particular, future research will be needed to establish how OGT and OGA inte

• JWH 133 The totality of evidence from randomized clinical tr

  2019-11-29

  

  The totality of evidence from randomized clinical trials supports the premise that worsening JWH 133 failure is a class effect of DPP-4 inhibitors. A meta-analysis by Verma et al. (54) of 100 randomized controlled clinical trials reported that the use of DPP-4 inhibitors was accompanied a significan

• Due to cell cell interactions

  2019-11-28

  

  Due to cell-cell interactions, high concentrations of LTs can be locally generated in a short period of time during an inflammatory response, thus potentiating LT function. The cellular communication can be mediated between immune cells as well as between immune cells other cell types. Several studi

• CPG a metalloenzyme derived from sp was the elected enzyme

  2019-11-28

  

  CPG2, a metalloenzyme derived from sp., was the elected enzyme for the first pilot-scale clinical trial of ADEPT. This enzyme has no mammalian homologue and activates glutamic Sometimes prodrug derivatives of several nitrogen mustards alkylating agents., , , , , A bond cleavable by CPG2 is essentia

• Haggar et al reported the synthesis

  2019-11-28

  

  Haggar et al. reported the synthesis of two new series of 8-(2-imino/oxo/thioxo pyrimidin-4-yl)-4-methyl-6-nitro-2-oxo-2H-chromen-7-yl benzoates 56 (X=O, S, NH) and 8-(pyrazol-3-yl)-4-methyl-6-nitro-2-oxo-2H-chromen-7-yl benzoates 57 [Y=C(O)CH3, 2,4-(NO2)2C6H3]. The 8-acetyl-4-methyl-6-nitro-2-oxo-2

• br Results and discussion br Conclusion In this investigatio

  2019-11-28

  

  Results and discussion Conclusion In this investigation, pharmacophore models of CK1 inhibitors were developed using a pharmacophore modeling protocol proposed by us. The optimal pharmacophore hypothesis, Hypo2, was adopted to retrieve potential CK1 inhibitors from the commercial chemical data

• We further verified the presence of CLIC CLIC

  2019-11-28

  

  We further verified the presence of CLIC1, CLIC4 and CLIC5 in purified mitochondria following protocols described earlier (Singh et al., 2012). As shown in Fig. 4, CLIC4 and CLIC5 were present in the ultra-pure mitochondrial fraction (M3). All the three fractions obtained from 30% (v/v) Percoll grad

• br Acknowledgements The authors thank Drs C Klein I Canisso

  2019-11-28

  

  Acknowledgements The authors thank Drs. C. Klein, I. Canisso and A. Claes with assistance in obtaining tissues. Supported by the Albert G. Clay Endowment, University of Kentucky. Introduction Neoplastic cells often develop drug resistance during tumor progression or cancer treatment (Turner a

• Our finding that activating DDR variants are a cause

  2019-11-28

  

  Our finding that activating DDR2 variants are a cause of this disease suggested that the ABL inhibitor dasatinib, a leukemia drug that also inhibits DDR2, could be used for treatment of affected individuals.10, 11 To examine the effect of dasatinib on p.Leu610Pro- and p.Tyr740Cys-induced autophospho

• br Results br Discussion CCA is

  2019-11-28

  

  Results Discussion CCA is a fatal tumor originating from the intrahepatic bile duct and the prognosis is very poor (Hoyos et al., 2018). CCA is one of the most dangerous primary liver malignant tumors and the most common malignant tumor of the biliary tract worldwide. However, the underlying m

• br Acknowledgements Thanks are due to

  2019-11-28

  

  Acknowledgements Thanks are due to Science and Technology Development Fund – Egypt for the Research Support Technology Development Grant (RSTDG) no. 12626. Our deep thanks and gratitude is also extended to National Cancer Institute (NCI), Bethesda, Maryland, USA for performing the anticancer eval

15481 records 886/1033 page Previous Next First page 上5页 886887888889890 下5页 Last page